Clinical studies show that Cagrilintide + GLPs (semaglutide, tirzepatide, retatrutide) produces significantly more weight loss than GLPs alone.
Well tolerated — most side effects are mild GI symptoms (nausea, constipation, similar to GLP-1s).
Seen as one of the most promising next-generation weight-loss peptides in development.